Trial Profile
A Phase I Clinical Trial Combining Anti-PD-1 Blocking Antibody, Anti-CD137 Agonistic Antibody and Adoptive Cell Therapy for Metastatic Melanoma
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2013
Price :
$35
*
At a glance
- Drugs CD137 antigen agonists (Primary) ; Nivolumab (Primary) ; Tumour infiltrating lymphocytes (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 12 Aug 2013 New trial record